EUVIMEDEUVIMED entdecken
Open Access

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties

Ying Cui iD, Bo Huang iD, Gaohong Dong, Ryuji Uozumi iD, Lu Tian iD

Statistics in Medicine · 2025

DOI: 10.1002/sim.70180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistics in Medicine, 2025. Verfasst von Ying Cui und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Data Science, Stanford University, Stanford, California, USA. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Models, Statistical. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In clinical trials, multiple outcomes of different priorities commonly occur as the patient's response may not be adequately characterized by a single outcome. Win statistics are appealing summary measures for between‐group difference at more than one endpoint. When defining the result of pairwise comparisons of a time‐to‐event endpoint, it is desirable to allow ties to account for incomplete follow‐up and not clinically meaningful difference in endpoints of interest. In this article, we propose a class of win statistics for time‐to‐event endpoints with a user‐specified equivalence margin. These win statistics are identifiable in the presence of right censoring and do not depend on the censoring distribution. We then develop estimation and inference procedures for the proposed win statistics based on inverse‐probability‐of‐censoring weighting adjustment to handle right censoring. We conduct extensive simulations to investigate the operational characteristics of the proposed procedure in the finite sample setting. A real oncology trial is used to illustrate the proposed approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicModels, StatisticalHumansComputer SimulationData Interpretation, StatisticalEndpoint Determination

Stichwörter der Autor:innen

equivalence marginrandomized clinical trialsright censoringwin ratiowin statistics

Autor:innen und Institutionen

  • Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
  • Pfizer Research & Development, Pfizer Inc., New York, New York, USA.
  • Sarepta Therapeutics Inc., Cambridge, Massachusetts, USA.
  • Department of Industrial Engineering and Economics, Institute of Science Tokyo, Tokyo, Japan.

ORCID-Profile: Ying Cui, Bo Huang, Ryuji Uozumi, Lu Tian

Förderung

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Cui, Y., Huang, B., Dong, G., Uozumi, R., & Tian, L. (2025). An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties. Statistics in Medicine. https://doi.org/10.1002/sim.70180

Vancouver

Cui Y, Huang B, Dong G, Uozumi R, Tian L. An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties. Statistics in Medicine. 2025. doi:10.1002/sim.70180

BibTeX
@article{Cui2025,
  author = {Cui, Ying and Huang, Bo and Dong, Gaohong and Uozumi, Ryuji and Tian, Lu},
  title = {An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties},
  journal = {Statistics in Medicine},
  year = {2025},
  doi = {10.1002/sim.70180}
}
Kostenlos starten →